Ignite Creation Date:
2024-05-06 @ 7:34 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06056752
Status:
RECRUITING
Last Update Posted:
2023-10-24
First Post:
2023-09-21
Brief Title:
QH103 Cell Injection for the Treatment of RelapsedRefractory B-cell Acute Lymphoblastic Leukemia
Sponsor:
Anhui Provincial Hospital
Organization:
Anhui Provincial Hospital
Study Overview
Official Title:
A Dose-escalation Clinical Study of QH103 Cell Injection CD19 CAR-γδT Cell Injection in Patients With RelapsedRefractory B-cell Acute Lymphoblastic Leukemia B-ALL
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-arm single-center interventional dose-escalation clinical study designed to evaluate the safety and tolerability of QH103 Cell Injection in the treatment of patients with relapsedrefractory B-cell acute lymphoblastic leukemia
Detailed Description:
To evaluate the safety and tolerability of QH103 Cell Injection in the treatment of relapsedrefractory CD19-positive B-cell acute lymphoblastic leukemia and to evaluate dose-limiting toxicity and maximum tolerated dose
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None